227 related articles for article (PubMed ID: 3156109)
1. Hypoxic cell radiosensitizers: expectations and progress in drug development.
Coleman CN
Int J Radiat Oncol Biol Phys; 1985 Feb; 11(2):323-9. PubMed ID: 3156109
[TBL] [Abstract][Full Text] [Related]
2. Clinical trials with hypoxic cell sensitizers: time to retrench or time to push forward?
Urtasun RC; Coleman CN; Wasserman TH; Phillips TL
Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1691-6. PubMed ID: 6237083
[TBL] [Abstract][Full Text] [Related]
3. Response of murine tumours to combinations of CCNU with misonidazole and other radiation sensitizers.
Siemann DW
Br J Cancer; 1982 Feb; 45(2):272-81. PubMed ID: 6460517
[TBL] [Abstract][Full Text] [Related]
4. Sensitizers and radiation dose fractionation: results and interpretations.
Hill RP
Int J Radiat Oncol Biol Phys; 1986 Jul; 12(7):1049-54. PubMed ID: 2943705
[TBL] [Abstract][Full Text] [Related]
5. Sensitizers and protectors in radiotherapy.
Brown JM
Cancer; 1985 May; 55(9 Suppl):2222-8. PubMed ID: 2983876
[TBL] [Abstract][Full Text] [Related]
6. Chemical sensitizers for hypoxic cells: a decade of experience in clinical radiotherapy.
Dische S
Radiother Oncol; 1985 Feb; 3(2):97-115. PubMed ID: 3157206
[TBL] [Abstract][Full Text] [Related]
7. [Present status of radiation sensitizers--hypoxic cell radiosensitizer].
Murayama C; Mori T
Gan To Kagaku Ryoho; 1989 Jun; 16(6):2135-41. PubMed ID: 2660744
[TBL] [Abstract][Full Text] [Related]
8. [Present status of hypoxic cell sensitizers and PLDR inhibitors].
Ono K; Sasai K; Shibamoto Y; Tsutsui K; Fushiki M; Nishidai T; Takahashi M; Abe M
Gan No Rinsho; 1987 Oct; 33(13):1673-8. PubMed ID: 2961900
[TBL] [Abstract][Full Text] [Related]
9. A comparison of the ability of some radiosensitizers undergoing clinical trials to act as chemosensitizers.
Hinchliffe M; McNally NJ
Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1635-40. PubMed ID: 6237081
[TBL] [Abstract][Full Text] [Related]
10. The multi-dose clinical tolerance and pharmacokinetics of the combined radiosensitizers, Ro 03-8799 (pimonidazole) and SR 2508 (etanidazole).
Newman HF; Ward R; Workman P; Bleehen NM
Int J Radiat Oncol Biol Phys; 1988 Nov; 15(5):1073-83. PubMed ID: 2972667
[TBL] [Abstract][Full Text] [Related]
11. Depletion of glutathione in vivo as a method of improving the therapeutic ratio of misonidazole and SR 2508.
Yu NY; Brown JM
Int J Radiat Oncol Biol Phys; 1984 Aug; 10(8):1265-9. PubMed ID: 6236185
[TBL] [Abstract][Full Text] [Related]
12. [Recent advances in hypoxic cell radiosensitizer].
Ono K; Takahashi M; Nishidai T; Shibamoto Y; Abe M
Gan No Rinsho; 1983 Oct; 29(13):1608-12. PubMed ID: 6230470
[TBL] [Abstract][Full Text] [Related]
13. Clinical trials of radiosensitizers: what should we expect?
Brown JM
Int J Radiat Oncol Biol Phys; 1984 Mar; 10(3):425-9. PubMed ID: 6231272
[TBL] [Abstract][Full Text] [Related]
14. A phase I study of the combination of two hypoxic cell radiosensitizers, Ro 03-8799 and SR-2508: toxicity and pharmacokinetics.
Newman HF; Bleehen NM; Workman P
Int J Radiat Oncol Biol Phys; 1986 Jul; 12(7):1113-6. PubMed ID: 2943709
[TBL] [Abstract][Full Text] [Related]
15. Modification of alkylating agent induced cell kill by 2-nitroimidazoles in unclamped and clamped SC 9L tumors.
Wallen CA; Moore SK; Wheeler KT
Int J Radiat Oncol Biol Phys; 1992; 22(4):727-30. PubMed ID: 1531976
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of nitroimidazole hypoxic cell radiosensitizers in a human tumor cell line high in intracellular glutathione.
DeGraff WG; Russo A; Gamson J; Mitchell JB
Int J Radiat Oncol Biol Phys; 1989 Apr; 16(4):1021-4. PubMed ID: 2522917
[TBL] [Abstract][Full Text] [Related]
17. Hypoxic sensitizer and cytotoxin for head and neck cancer.
Lee DJ; Moini M; Giuliano J; Westra WH
Ann Acad Med Singap; 1996 May; 25(3):397-404. PubMed ID: 8876907
[TBL] [Abstract][Full Text] [Related]
18. Studies in radiosensitizing effects of misonidazole and SR-2508 on C3H/He mouse mammary tumors.
Ono K; Takahashi M; Nishidai T; Dodo Y; Shibamoto Y; Hiraoka M; Yukawa Y; Abe M
Radiat Med; 1984; 2(1):71-5. PubMed ID: 6242712
[TBL] [Abstract][Full Text] [Related]
19. Final report of the phase I trial of the hypoxic cell radiosensitizer SR 2508 (etanidazole) Radiation Therapy Oncology Group 83-03.
Coleman CN; Wasserman TH; Urtasun RC; Halsey J; Noll L; Hancock S; Phillips TL
Int J Radiat Oncol Biol Phys; 1990 Feb; 18(2):389-93. PubMed ID: 2154420
[TBL] [Abstract][Full Text] [Related]
20. [Radiosensitizer: hypoxic cell radiosensitizer].
Mori T
Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-2):1399-404. PubMed ID: 2525001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
